

KLCI: 1163.79

Bloomberg: PHRM MK

# Results Update

Monday, 24 August 2009



enara TA One, 22 Jalan P Ramie 50250 Kuala Lumpur. Malaysia Tel: 603 - 2072 1277 Fax: 603 - 2032 5048

> Analyst: TA Research Tel: 20721277 ext: 1616 e-mail: ikmalhafizi@ta.com.my

Get your facts before you invest

Sector: Pharmaceutical

Share Price: RM4.40

Target Price: RM3.95 Market Capitalisation: RM107mn

> Recommendation: SELL Stock code: 8133

Board: Main



## Pharmaniaga Berhad

Results Within Target

**Key Stock Statistics** 

		2007	2008	2009F	
EPS	(sen)	46.8	56.1	60.7	
P/E	(x)	7.5	6.3	5.8	
Div / Share	(sen)	18.0	11.9	18.2	
BV / Share	(sen)	3.4	3.6	4.2	
Issued Capital	(mn)	107			
52 weeks price	(%)	4.04 /			
Major shareholders	Khazanah - 86%				


#### Per Share Data

	2007	2008F	2009F	2010F	
(sen)	3.4	3.6	4.2	4.9	
(sen)	- 1.2	35.0	122.3	180.9	
(sen)	46.8	56.1	60.7	100.8	
(sen)	18.0	11.9	18.2	30.2	
(%)	5.1	3.4	5.2	8.6	
(x)	7.5	0.1	5.8	3.5	
(%)	15.6	11.1	15.2	21.4	
	(sen) (sen) (sen) (sen) (%) (x)	(sen) 3.4 (sen) - 1.2 (sen) 46.8 (sen) 18.0 (%) 5.1 (x) 7.5	(sen)     3.4     3.6       (sen)     - 1.2     35.0       (sen)     46.8     56.1       (sen)     18.0     11.9       (%)     5.1     3.4       (x)     7.5     0.1	(sen)     3.4     3.6     4.2       (sen)     - 1.2     35.0     122.3       (sen)     46.8     56.1     60.7       (sen)     18.0     11.9     18.2       (%)     5.1     3.4     5.2       (x)     7.5     0.1     5.8	(sen)     3.4     3.6     4.2     4.9       (sen)     - 1.2     35.0     122.3     180.9       (sen)     46.8     56.1     60.7     100.8       (sen)     18.0     11.9     18.2     30.2       (%)     5.1     3.4     5.2     8.6       (x)     7.5     0.1     5.8     3.5

P&L Analysis (RM mil)

	2007	2008F	2009F	2010F
Revenue	1184.0	1305.6	1482.8	1646.6
Cost of Revenue	1080.8	1073.8	1366.8	1473.5
EBITDA	103.2	101.5	115.9	173.0
Net Interest	5.4	9.7	7.2	5.4
Depreciation	21.6	21.9	22.3	22.7
Net Profit	50.1	60.0	64.9	107.8

### **Share Price chart**



Source : Bloomberg

#### 2Q09 Results Analysis

	Cumulative 2Q					
YE 31 December	2Q09	1Q09	Q0Q%	FY09	FY08	YOY%
Turnover	333.2	313.72	6%	646.93	663.11	-2%
EBIT	25.4	21.36	19%	46.8	51.5	-9%
Interest Inc/(exp)	-1.1	-1.18	-8%	-2.26	-3.00	-25%
Pretax	24.3	20.18	21%	44.52	48.46	-8%
Taxation	-5.8	-5.49	6%	-11.30	-16.00	-29%
Net Profit	17.7	14.52	22%	32.22	31.62	2%
EPS (sen)	16.5	13.57	22%	30.12	29.59	2%
EBIT Margin (%)	8%	7%		7%	8%	
Pretax Margi (%)	7%	6%		7%	7%	
Tax Rate (%)	24%	27%		25%	33%	

#### Review

- Pharmaniaga's 2Q09 results were announced last Friday. The group made RM17.697mn in net profit (or 16.54sen per share). The performance is backed by revenue of RM333.21mn.
- The results came well within our estimate as it covers 26% of our full year estimate of RM64.9mn in net income.
- Compared to the preceding quarter, the group had a marginal revenue increase of 6%. Net income outpaced revenue with 22% increment QoQ.
- However, against last year, the group's revenue dipped 2% although net profit has increased by 2%.
- Margin during the year remained stable despite the tough economic condition, partly because of the group's ability to pass on some of the increase in costs to consumers.



#### Impact

At this juncture we are leaving our FY09 numbers intact.

#### Outlook

 The company has requested for an extension of its listing status considering the breach of public shareholding spread currently. This is still a concerning issue, plaguing sentiment of its share trading activities.

#### Valuation

• We maintain our target price at RM3.95 as no revision in our numbers is warranted. We based this on a PER multiple of 6.5x. We maintain our SELL call on the group.

#### Disclaimer

The information in this report has been obtained from sources believed to be reliable. Its accuracy or completeness is not guaranteed and opinions are subject to change without notice. This report is for information only and not to be construed as a solicitation for contracts. We accept no liability for any direct or indirect loss arising from the use of this document. We, our associates, directors, employees may have an interest in the securities and/or companies mentioned herein.

This report has been prepared by TA Securities Holdings Berhad for purposes of CMDF-Bursa Research Scheme ("CBRS") administered by Bursa Malaysia Berhad and has been compensated to undertake the scheme. TA Securities Holdings Berhad has produced this report independent of any influence from CBRS or the subject company.

For more information about CBRS and other research reports, please visit Bursa Malaysia's website at: <a href="http://www.bursamalaysia.com/website/bm/listed\_companies/cmdf\_bursa\_research\_scheme/">http://www.bursamalaysia.com/website/bm/listed\_companies/cmdf\_bursa\_research\_scheme/</a>

for TA SECURITIES HOLDINGS BERHAD(14948-M)

(A Participating Organisation of Bursa Malaysia Securities Berhad)

Yaw Chun Soon, Executive Director – Operations